MBRX: Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for MBRX
Across the 29 sessions after earlier MBRX headlines, the stock closed higher 11 times and lower 17 times, with a median move of 5.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | MBRX | SPY |
|---|---|---|---|
| Oct 30, 2026 | Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027 | -9.4% | -1.8% |
| Oct 20, 2026 | Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial | +16.8% | +0.3% |
| Oct 16, 2026 | Moleculin Announces Reverse Stock Split | -24.2% | -1.1% |
| Oct 7, 2026 | Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit | -1.5% | -0.2% |
| Sep 29, 2026 | Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout | -7.5% | -0.2% |
| Sep 28, 2026 | Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine | -5.4% | -0.7% |
Quantisnow market dataNASDAQ
MBRX
Moleculin Biotech Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2016
Get push alerts for MBRX
Full MBRX profile on Quantisnow Follow MBRX and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time